Attaining LDL-C <50 mg/dl with rosuvastatin significantly reduced cardiovascular events compared to placebo (HR 0.35; 95% CI 0.25-0.49; p<0.0001) without increasing reported adverse events.
RCT
Does attaining LDL-C <50 mg/dl with rosuvastatin reduce cardiovascular events without increasing adverse events in apparently healthy adults with elevated hsCRP?
17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C <130 mg/dl
Rosuvastatin 20 mg daily (categorized by attaining follow-up LDL-C <50 mg/dl)
Placebo
Primary trial endpoint (major cardiovascular events)composite
Attaining LDL-C <50 mg/dl with rosuvastatin in apparently healthy adults with elevated hsCRP is associated with a substantially lower risk of cardiovascular events and all-cause mortality without a systematic increase in adverse events.
OBJECTIVES: The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. BACKGROUND: The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current recommended targets remain uncertain. METHODS: A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C <130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-cause mortality, major cardiovascular events, and adverse events. In a post-hoc analysis, participants allocated to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level <50 mg/dl. RESULTS: During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C <50 mg/dl (n = 4,000) or with LDL-C <50 mg/dl (n = 4,154), respectively (fully-adjusted hazard ratio: 0.76; 95% confidence interval: 0.57 to 1.00 for subjects with no LDL-C <50 mg/dl vs. placebo and 0.35, 95% confidence interval: 0.25 to 0.49 for subjects attaining LDL-C <50 mg/dl; p for trend <0.0001). For all-cause mortality, corresponding event rates were 0.67, 0.65, and 0.39 (p for trend = 0.004). Rates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-allocated participants with and without LDL-C <50 mg/dl. CONCLUSIONS: Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein ≥2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.
Building similarity graph...
Analyzing shared references across papers
Judith Hsia
Jean MacFadyen
John T. Monyak
Journal of the American College of Cardiology
Harvard University
Brigham and Women's Hospital
AstraZeneca (United States)
Building similarity graph...
Analyzing shared references across papers
Hsia et al. (Fri,) conducted a rct in Apparently healthy adults with elevated hsCRP (n=17,802). Rosuvastatin vs. Placebo was evaluated on Primary trial endpoint (major cardiovascular events) (HR 0.35, 95% CI 0.25-0.49, p=<0.0001). Attaining LDL-C <50 mg/dl with rosuvastatin significantly reduced cardiovascular events compared to placebo (HR 0.35; 95% CI 0.25-0.49; p<0.0001) without increasing reported adverse events.
www.synapsesocial.com/papers/69ecdb64eb2c6328dba62cd2 — DOI: https://doi.org/10.1016/j.jacc.2010.09.082